Poudrier G, Nolan IT, Cook TE, et al. Assessing quality of life and patient-reported satisfaction with masculinizing top surgery: a mixed-methods descriptive survey study. Plast Reconstr Surg. 2019;143(1):272–9.
2.Thoreson N, Marks DH, Peebles JK, King DS, Dommasch E. health insurance coverage of permanent hair removal in transgender and gender-minority patients. JAMA Dermatol. 2020;156(5):561–5.
3.Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
4.Sabra JJ, Fang CX, Kundu RV. A knowledge-based assessment of dermatological care for transgender women. Transgend Health. 2018;3(1):71–3.
5.Buhalog B, Peebles JK, Mansh M, et al. Trainee exposure and education for minimally invasive gender-affirming procedures. Dermatol Clin. 2020;38(2):277–83.
6.Cho SW, Jin HR. Feminization of the forehead in a transgender: frontal sinus reshaping combined with brow lift and hairline lowering. Aesthetic Plast Surg. 2012;36(5):1207–10.
7.Nakamura A, Watanabe M, Sugimoto M, et al. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J. 2013;60(3):275–81.
8.Vilenchik V, Thomas K, Baker L, Hitchens E, Keith D. Laser therapy is a safe and effective treatment for unwanted hair in adults undergoing male to female sex reassignment. Clin Exp Dermatol. 2021;46(3):541–3.
9.Kirisawa T, Ichihara K, Sakai Y, Morooka D, Iyoki T, Masumori N. Physical and psychological effects of gender-affirming hormonal treatment using intramuscular testosterone enanthate in Japanese transgender men. Sex Med. 2021;9(2):100306.
10.Downing JM, Yee K, Dy G. Hair removal for patients undergoing feminizing surgeries in oregon’s medicaid program. JAMA Dermatol. 2021;157(3):346–8.
11.Pigot GLS, Belboukhaddaoui S, Bouman MB, et al. Effectiveness of preoperative depilation of the urethral donor site for phalloplasty: neourethral hair growth and its effects on voiding. Eur Urol Focus. 2020;6(4):770–5.
12.Almazan AN, Benson TA, Boskey ER, Ganor O. Associations between transgender exclusion prohibitions and insurance coverage of gender-affirming surgery. LGBT Health. 2020;7(5):254–63.
13.Marks DH, Hagigeorges D, Manatis-Lornell AJ, Dommasch E, Senna MM. Excess hair, hair removal methods, and barriers to care in gender minority patients: A survey study. J Cosmet Dermatol. 2020;19(6):1494–8.
14.Garcia-Rodriguez L, Thain LM, Spiegel JH. Scalp advancement for transgender women: Closing the gap. Laryngoscope. 2020;130(6):1431–5.
15.Ngaage LM, McGlone KL, Xue S, et al. Gender surgery beyond chest and genitals: current insurance landscape. Aesth Surg J. 2020;40(4):NP202–10.
16.Ristori J, Cocchetti C, Castellini G, et al. Hormonal treatment effect on sexual distress in transgender persons: 2-year follow-up data. J Sex Med. 2020;17(1):142–51.
17.Marks DH, Hagigeorges D, Manatis-Lornell AJ, Dommasch E, Senna MM. Hair loss among transgender and gender-nonbinary patients: a cross-sectional study. Br J Dermatol. 2019;181(5):1082–3.
18.Jain J, Kwan D, Forcier M. Medroxyprogesterone acetate in gender-affirming therapy for transwomen: results from a retrospective study. J Clin Endocrinol Metab. 2019;104(11):5148–56.
19.Imhof R, Miest R, Davidge-Pitts C, Nippoldt T, Tollefson M. Dermatological disorders in transgender patients. J Amer Acad Dermatol. 2019;81(4):AB44.
20.Peloza K, Kahn B, Yeung H. Insurance coverage for hair removal therapies for the care of transgender patients. J Amer Acad Dermatol. 2019;81(4):AB83.
21.Stoffers IE, de Vries MC, Hannema SE. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria. J Sex Med. 2019;16(9):1459–68.
22.Motosko CC, Zakhem GA, Pomeranz MK, et al. Effect of testosterone on chests and abdomens of transgender men. J Am Acad Dermatol. 2019;81(2):634–6.
23.Bradford NJ, Rider NG, Spencer KG. Hair removal and psychological well-being in transfeminine adults: associations with gender dysphoria and gender euphoria. J Dermatol Treat. 2019. https://doi.org/10.1080/09546634.2019.1687823.
24.Butler RM, Horenstein A, Gitlin M, et al. Social anxiety among transgender and gender nonconforming individuals: The role of gender-affirming medical interventions. J Abnorm Psychol. 2019;128(1):25–31.
25.Testa RJ, Rider GN, Haug NA, Balsam KF. Gender confirming medical interventions and eating disorder symptoms among transgender individuals. Health Psychol. 2017;36(10):927–36.
26.Tack LJW, Heyse R, Craen M, et al. Consecutive cyproterone acetate and estradiol treatment in late-pubertal transgender female adolescents. J Sex Med. 2017;14(5):747–57.
27.Capitán L, Simon D, Meyer T, et al. Facial feminization surgery: simultaneous hair transplant during forehead reconstruction. Plast Reconstr Surg. 2017;139(3):573–84.
28.Fisher AD, Castellini G, Ristori J, et al. Cross-sex hormone treatment and psychobiological changes in transsexual persons: Two-year follow-up data. J Clin Endocrinol Metab. 2016;101(11):4260–9.
29.van de Grift TC, Cohen-Kettenis PT, Elaut E, et al. A network analysis of body satisfaction of people with gender dysphoria. Body Image. 2016;17:184–90.
30.Ginsberg BA, Calderon M, Seminara NM, Day D. A potential role for the dermatologist in the physical transformation of transgender people: A survey of attitudes and practices within the transgender community. J Am Acad Dermatol. 2016;74(2):303–8.
31.Stevenson MO, Wixon N, Safer JD. Scalp hair regrowth in hormone-treated transgender woman. Transgender Health. 2016;1(1):202–4.
32.Wierckx K, Van de Peer F, Verhaeghe E, et al. Short- and long-term clinical skin effects of testosterone treatment in trans men. J Sex Med. 2014;11(1):222–9.
33.Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: Results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11(8):1999–2011.
34.Adenuga P, Summers P, Bergfeld W. Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy. J Am Acad Dermatol. 2012;67(3):e121–3.
35.Mueller A, Haeberle L, Zollver H, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med. 2010;7(9):3190–8.
36.Giltay EJ, Gooren LJ. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. J Clin Endocrinol Metab. 2000;85(8):2913–21.
37.Moreno-Arrones OM, Becerra A, Vano-Galvan S. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Clin Exp Dermatol. 2017;42(7):743–8.
38.Health WPAfT. Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People (7th Version). In: 2012.
39.Pallotti F, Senofonte G, Pelloni M, et al. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. Endocrine. 2020;68(3):688–94.
40.Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–46.
41.Motosko CC, Bieber AK, Pomeranz MK, Stein JA, Martires KJ. Physiologic changes of pregnancy: A review of the literature. Int J Womens Dermatol. 2017;3(4):219–24.
Comments (0)